Payment overview · 2025
General Payments
$2,507.76
66 reported records · 22 companies
Healthcare provider profile · identity verified
Rodolfo Alberto Herrera, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BEDFORD, TX · NPI 1154524668
Verified facts
What the public records show
CMS Open Payments records show Rodolfo Alberto Herrera, M.D. received $2,507.76 in general payments during 2025 across 66 reported records.
Spinal Simplicity, LLC accounted for 56.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Relistor, Roxybond, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Belbuca by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nucynta by this doctor in 2024.
PROTEGA PHARMACEUTIALS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ROXYBOND as an associated drug or biological on 2633 records involving 1078 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Roxybond by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Relistor by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Spinal Simplicity, LLC | Unresolved — no canonical attribution shown | $1,410.84 | 56.3% | 20 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $336.64 | 13.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.86 | 4.1% | 6 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $97.38 | 3.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.07 | 2.8% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $62.73 | 2.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $57.94 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.34 | 1.9% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.14 | 1.5% | 2 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $37.69 | 1.5% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.61 | 1.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.57 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.43 | 0.9% | 1 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $22.73 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.78 | 0.9% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.08 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.77 | 0.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.39 | 0.7% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $16.28 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.98 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.28 | 0.6% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $15.23 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,444.88 | 63 |
| Travel and Lodging | $1,062.88 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HA MINUTEMAN G3-R Normalized: ha minuteman g3 r |
Device | Spinal Simplicity, LLC | $1,410.84 | 20 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $194.06 | 3 | 2025 |
Source payment records
|
|||||
| LIBERTY SI Normalized: liberty si |
Device | Spinal Simplicity, LLC | $176.34 | 1 | 2025 |
Source payment records
|
|||||
| PATRIOT SI Normalized: patriot si |
Device | Spinal Simplicity, LLC | $176.34 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $97.38 | 4 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $85.15 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $62.73 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $62.32 | 3 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $57.94 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $53.46 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $40.52 | 3 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $38.14 | 2 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 169 | exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ROXYBOND roxybond |
2025 | Roxybond | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
169 | 41 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PROTEGA PHARMACEUTIALS INC Exact reporting entity; no affiliate inference |
2025 | ROXYBOND open payments reported associated product |
CMS Open Payments — General Payments 2633 supporting records · 1078 recipient NPIs · example record 1235986235 |
Roxybond · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2870 | 401 |
| Buprenorphine | Buprenorphine | 560 | 119 |
| Gabapentin | Gabapentin | 555 | 137 |
| Pregabalin | Pregabalin | 549 | 137 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 423 | 99 |
| Tizanidine Hcl | Tizanidine Hcl | 416 | 114 |
| Celecoxib | Celecoxib | 398 | 119 |
| Oxycodone Hcl | Oxycodone Hcl | 250 | 49 |
| Diazepam | Diazepam | 229 | 117 |
| Lidocaine | Lidocaine | 210 | 60 |
| Methocarbamol | Methocarbamol | 200 | 45 |
| Tramadol Hcl | Tramadol Hcl | 191 | 75 |
| Belbuca | Buprenorphine Hcl | 169 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 169 | 49 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 167 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 43 |
| Meloxicam | Meloxicam | 131 | 45 |
| Morphine Sulfate Er | Morphine Sulfate | 128 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 124 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 109 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 26 |
| Baclofen | Baclofen | 91 | 29 |
| Tramadol Hcl Er | Tramadol Hcl | 86 | 22 |
| Nucynta Er | Tapentadol Hcl | 85 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 18 |
| Methadone Hcl | Methadone Hcl | 63 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 54 | 14 |
| Linzess | Linaclotide | 53 | 14 |
| Ibuprofen | Ibuprofen | 50 | 14 |
| Naloxone Hcl | Naloxone Hcl | 50 | 50 |
| Lactulose | Lactulose | 49 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Xtampza Er | Oxycodone Myristate | 27 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 15 | 11 |
| Naproxen | Naproxen | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Naproxen Sodium Er | Naproxen Sodium | 13 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Relistor | Methylnaltrexone Bromide | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
| Roxybond | Oxycodone Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,507.76 · 66 records | Spinal Simplicity, LLC | BOTOX, Belbuca, Dexcom G6 Transmitter, EDARBYCLOR, ETERNA, GVOKE HYPOPEN, General - Pain Management, HA MINUTEMAN G3-R, HORIZANT, ID NOW INSTRUMENT, JOURNAVX, LIBERTY SI, Nalu Neurostimulation System, OCTRODE, Ozempic, PATRIOT SI, PROCLAIM, QUTENZA, RELISTOR, REXULTI, ROXYBOND, Rybelsus, TRINTELLIX, The Cologuard Plus Collection Kit, VRAYLAR, WAYRILZ, Wegovy, ZTLido | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error